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BACKGROUND: Current cell-free DNA assessment of fetal chromo- RESULTS: Clinical sensitivity within this study was determined to be
somes does not analyze and report on all chromosomes. Hence, a sig-
nificant proportion of fetal chromosomal abnormalities are not detectable
by current noninvasive methods. Here we report the clinical validation of a
novel noninvasive prenatal test (NIPT) designed to detect genomewide
gains and losses of chromosomal material 7 Mb and losses associated
with specific deletions <7 Mb.
OBJECTIVE: The objective of this study is to provide a clinical validation
of the sensitivity and specificity of a novel NIPT for detection of
genomewide abnormalities.
STUDY DESIGN: This retrospective, blinded study included
maternal plasma collected from 1222 study subjects with preg-
nancies at increased risk for fetal chromosomal abnormalities that
were assessed for trisomy 21 (T21), trisomy 18 (T18), trisomy 13
(T13), sex chromosome aneuploidies (SCAs), fetal sex, genomewide
copy number variants (CNVs) 7 Mb, and select deletions <7 Mb.
Performance was assessed by comparing test results with findings
from G-band karyotyping, microarray data, or high coverage
sequencing.Cite this article as: Lefkowitz RB, Tynan JA, Liu T, et al.
Clinical validation of a noninvasive prenatal test for
genomewide detection of fetal copy number variants. Am
J Obstet Gynecol 2016;215:227.e1-16.
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http://dx.doi.org/10.1016/j.ajog.2016.02.030100% for T21 (95% confidence interval [CI], 94.6e100%), T18 (95% CI,
84.4e100%), T13 (95%CI, 74.7e100%), and SCAs (95%CI, 84e100%),
and 97.7% for genomewide CNVs (95% CI, 86.2e99.9%). Clinical speci-
ficity within this study was determined to be 100% for T21 (95% CI,
99.6e100%), T18 (95%CI, 99.6e100%), and T13 (95%CI, 99.6e100%),
and 99.9% for SCAs and CNVs (95% CI, 99.4e100% for both). Fetal sex
classification had an accuracy of 99.6% (95% CI, 98.9e99.8%).
CONCLUSION: This study has demonstrated that genomewide NIPT
for fetal chromosomal abnormalities can provide high resolution, sensitive,
and specific detection of a wide range of subchromosomal and whole
chromosomal abnormalities that were previously only detectable by
invasive karyotype analysis. In some instances, this NIPT also provided
additional clarification about the origin of genetic material that had not
been identified by invasive karyotype analysis.
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Since its introduction in 2011, nonin-
vasive prenatal tests (NIPT) have had a
signiﬁcant impact on prenatal care. In
only 4 years, NIPT has evolved into a
standard option for high-risk pregnan-
cies.1 Content has also evolved from
exclusive trisomy 21 (T21) testing to
include trisomy 18 (T18), trisomy 13
(T13), sex chromosome aneuploidies
(SCAs), and select microdeletions.
This standard content can be expected
to detect 80-83% of chromosomal
abnormalities detected by karyotyping
in a general screening population,2-4however this leaves a gap of approxi-
mately 17-20% of alternative chromo-
somal/subchromosomal abnormalities
not detected. Consequently, obtaining
comprehensive information about the
genetic makeup of the fetus requires an
invasive procedure. To overcome these
limitations, NIPT could be extended to
cover the entire genome. However, it is
challenging to maintain a very high
speciﬁcity and positive predictive value
(PPV) when interrogating all accessible
regions in the genome.5 In previous re-
ports, we have overcome these technical
hurdles.6 Furthermore, a recent study by
Yin et al7 demonstrated feasibility for
noninvasive genomewide detection of
subchromosomal abnormalities. In this
report, we have improved the assay and
statistical methods to enable compre-
hensive genomewide detection of copy
number variants (CNVs) 7 Mb. We
present results of a large blinded clinical
study of >1200 samples including >100
samples with common aneuploidiesAUGUST 2016 Ameridetectable by traditional NIPT and >30
samples affected by subchromosomal
CNVs.
Materials and Methods
Study design
This blinded, retrospective clinical study
included samples from women consid-
ered at increased risk for fetal aneuploidy
based on advanced maternal age 35
years, a positive serum screen, an
abnormal ultrasound ﬁnding, and/or a
history of aneuploidy. Archived samples
were selected for inclusion in the study
by an unblinded internal third party
according to the requirements docu-
mented in the study plan. Samples were
then blind-coded to all operators and the
analysts who processed the samples. Af-
ter sequencing, an automated bioinfor-
matics analysis was performed to detect
whole chromosome aneuploidies and
subchromosomal CNVs. Results were
compiled electronically and were
reviewed by a subject matter expert whocan Journal of Obstetrics& Gynecology 227.e1
TABLE 1
Demographic and pregnancy-related data
Demographic Median Range
Maternal age, y (Ntotal ¼ 1177) 36.0 17.8e47
Gestational age, wk (Ntotal ¼ 1183) 17 8e38
Maternal weight, lb (Ntotal ¼ 1168) 150 93e366
Procedure Percent (Naffected/Ntotal)
CVS 14.5 (175/1203)
Amniocentesis 85.2 (1025/1203)
Both 0.2 (3/1203)
Confirmation Percent (Naffected/Ntotal)
Karyotype 90.4 (1089/1205)
Microarray 5.8 (70/1205)
Both 3.8 (46/1205)
Choice of invasive procedure, choice of diagnostic test, and demographic data were not available for all 1208 samples included
in study.
Naffected refers to the number of samples with the indicated procedure or confirmation; Ntotal refers to number of samples
where that data were available.
CVS, chorionic villus sampling.
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manual review mimics the process in the
clinical laboratory, where cases are
reviewed by a laboratory director before
a result is signed out. Completed classi-
ﬁcation results were provided to the in-
ternal third party for determination of
concordance. Analyzed samples had
conﬁrmation of positive or negative
events by either G-band karyotype or
microarray ﬁndings from samples
collected through either chorionic villus
sampling (CVS) or amniocentesis.
Circulating cell-free “fetal” DNA is
believed to originate largely from
placental trophoblasts. Genetic differ-
ences between the fetus and the placenta
can occur (eg, conﬁned placental mosa-
icism), leading to discordance between
NIPT results and cytogenetic studies on
amniocytes or postnatally obtained
samples.8 Results from CVS by chro-
mosomal microarray were thus consid-
ered the most accurate ground truth.
Therefore, discordant results originating
from amniocytes (karyotype or micro-
array) were resolved by sequencing at
high coverage (an average of 226 million
reads per sample). Sequencing depth has
been shown as the limiting factor in
NIPT methods, with increased depth
allowing improved detection of events in
samples with lower fetal fractions or
improved detection of smaller events.9
High coverage sequencing has been
used in multiple studies to unambigu-
ously identify subchromosomal
events6,10-12 and was used here as a
reference for performance evaluation in
discrepant amniocentesis samples.
Details of the sample demographics
are described in Table 1. Indications for
invasive testing are described in Table 2.
Sample collection
In total, 1222 maternal plasma samples
were previously collected using 4 inves-
tigational review board (IRB)-approved
protocols with a small subset (9 samples)
comprising remnant plasma samples
collected from previously consented pa-
tients in accordance with the Food and
Drug Administration guidance on
informed consent for in vitro diagnostic
devices using leftover human specimens
that are not individually identiﬁable.13227.e2 American Journal of Obstetrics& GynecolSamples from 2 of the protocols (Com-
pass IRB no. 00508 and Western IRB no.
20120148) were collected from high-risk
pregnant subjects prior to undergoing a
conﬁrmatory invasive procedure (1189
samples). Samples from the other 2
protocols (Compass IRB no. 00351 and
Columbia University IRB no.
AAAN9002) came from subjects who
were enrolled in the studies after
receiving the fetal karyotype and/or
microarray results of a conﬁrmatory
invasive procedure (24 samples). All
subjects provided written informed
consent prior to undergoing any study-
related procedures. A total of 5321
high-risk subjects were recruited into the
4 clinical studies indicated above at the
time of sample selection. To be eligible
for inclusion into this study, subjects had
to havemet all protocol inclusion and no
exclusion criteria, have fetal outcome
determined by karyotype and/or micro-
array, and have at least 1 plasma aliquot
of 3.5 mL obtained from whole blood
collected in a BCT tube (Streck, Omaha,
NE). There was no sample selection
preference based on high-risk indica-
tion. All subjects meeting these selection
criteria with an abnormal fetal outcome
as needed for the study were identiﬁedogy AUGUST 2016and pulled from inventory. These were
then supplemented with randomly
selected subjects with samples meeting
the same selection criteria but with a
normal karyotype to reach the total of
1222 samples for testing.
Library preparation, sequencing,
and analytical methods
Libraries were prepared and quantiﬁed as
described byTynan et al.14 To reduce noise
and increase signal, sequencing depth for
this analysis was increased to target 32
million reads per sample. Sequencing
reads were aligned to hg19 using Bowtie
2.15Thegenomewas thenpartitioned into
50-kbp nonoverlapping segments and the
total number of reads per segment was
determined, by counting the number of
reads with 5’ ends overlapping with a
segment. Segments with high read count
variability or low mapability were
excluded. The 50 kbp read counts were
then normalized to remove coverage and
guanine/cytosine biases and other higher-
order artifacts using the methods previ-
ously described in Zhao et al.6
The presence of fetal DNA was quan-
tiﬁed using the regional counts of whole
genome single-end sequencing data as
described by Kim et al.16
TABLE 2
Indications for testing
Indication Euploid, n ¼ 1009 T21, n ¼ 87 T18, n ¼ 29 T13, n ¼ 15 SCA, n ¼ 26 CNV, n ¼ 44 Total, n ¼ 1210
Positive serum screening 404 (40%) 36 (41.4%) 13 (44.8%) 4 (26.7%) 3 (11.5%) 16 (36.4%) 476 (39.3%)
Maternal age >35 y 418 (41.4%) 28 (32.2%) 10 (34.5%) 4 (26.7%) 2 (7.7%) 10 (22.7%) 472 (39%)
Ultrasound abnormality 152 (15.1%) 34 (39.1%) 6 (20.7%) 10 (66.7%) 16 (61.5%) 22 (50%) 239 (19.8%)
Family history 33 (3.3%) 4 (4.6%) 1 (3.4%) 0 (0%) 1 (3.8%) 1 (2.3%) 40 (3.3%)
Not specified 85 (8.4%) 11 (12.6%) 5 (17.2%) 2 (13.3%) 4 (15.4%) 2 (4.5%) 109 (9%)
Each cell lists count (%) of indication within chromosome category. Samples may have multiple indications for testing and therefore do not sum to 100%. As 2 T18 samples also had SCA, total number
of abnormalities and euploid samples sum to 1210.
CNV, copy number variant; SCA, sex chromosome aneuploidy; T13, trisomy 13; T18, trisomy 18; T21, trisomy 21.
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Circular binary segmentation (CBS) was
used to identify CNVs throughout the
entire genome by segmenting each
chromosome into contiguous regions of
equal copy number.17 A segment-
merging algorithm was then used to
compensate for oversegmentation by
CBS when the signal-to-noise ratio was
low.18 Z-scores were calculated for both
CBS-identiﬁed CNVs and whole chro-
mosome variants by comparing the
signal amplitude with a reference set of
samples in the same region. The
measured Z-scores form part of an
enhanced version of Chromosomal Ab-
erration Decision Tree previously
described in detail in Zhao et al.6
To further improve speciﬁcity of CNV
detection, bootstrap analysis was per-
formed as an additional measure for the
conﬁdence of the candidate CNVs. The
within sample read count variability was
compared to a normal population (rep-
resented by 371 euploid samples) and
quantiﬁed by bootstrap conﬁdence level.
To assess within sample variability, the
bootstrap resampling described below
was applied to every candidate CNV.
For each identiﬁed segment within the
CNV, the median shift of segment frac-
tion from the normal level across the
chromosome was calculated. This me-
dian shift was then corrected to create a
read count baseline for bootstrapping.
Next, a bootstrapped segment of the
same segment length as the candi-
date CNV was randomly sampled with
replacement from the baseline readcounts. The median shift was then
applied to this bootstrapped fragment.
The segment fraction of the boot-
strapped fragment was calculated as
follows:
segment fraction
¼
P
read counts within segment
P
read counts across the autosome
This process was repeated 1000 times
to generate a bootstrap distribution of
segment fractions for an affected popu-
lation. A normal reference distribution
was created based on the segment frac-
tion of the same location as the candidate
CNV in 371 euploid samples. A
threshold was then calculated as the
segment fraction that was at least 3.95
median absolute deviations away from
the median segment fraction of the
reference distribution. Lastly, the boot-
strap conﬁdence level was calculated as
the proportion of bootstrap segments
whose fractions had absolute z-statistics
above the signiﬁcance threshold.
A whole chromosome or sub-
chromosomal abnormality is detected as
described in Zhao et al.6
Results
The study comprised a total of 1222
maternal plasma samples. After
unblinding, 11 samples were excluded
because they had no or insufﬁcient
karyotype or microarray information
(Figure 1) and 3 samples were excluded
because of conﬁrmed mosaicism.
Of the remaining 1208 samples, 42
were ﬂagged as nonreportable usingAUGUST 2016 Ameriquality criteria that had been established
prior to analysis, leaving 1166 reportable
samples for analyses comprising 13%
(n ¼ 153) of samples with common
whole chromosome 21, 18, 13, X, or Y
aneuploidies and 3.6% (n ¼ 43) of
samples with subchromosomal CNVs or
rarer whole chromosome aneuploidies.
Technical failure criteria included but
were not limited to: low library concen-
tration, low raw autosomal counts, high
GC bias, poor normalization, and high
bin variability (Figure 1). Biological
failure criteria included low fetal fraction
(<4%) and large maternal CNV events.
Themost common reason for failure was
low fetal fraction (n ¼ 11). During re-
view of the data, 1 sample was signed out
as T18 (and was included in the analyzed
cohort), even though it did not meet the
autosomal countminimum. This sample
had sufﬁcient counts for the determi-
nation of standard aneuploidies, but not
sufﬁcient counts for the detection of
subchromosomal CNVs. The 42 non-
reportable samples showed no evidence
of enrichment for whole chromosome/
subchromosomal positive samples
(5 positive of 42 nonreportable samples
vs 204 positive of 1166 reportable
samples). Details of nonreportable and
excluded samples are provided in
Supplemental Table 1. Concordant with
previous studies, the overall reportable
rate on ﬁrst aliquots of maternal plasma
was 96.5%. The overall no-call rate per
patient is expected to be approximately
1% when a second aliquot is available,
based on published clinical laboratory
experience.19can Journal of Obstetrics& Gynecology 227.e3
FIGURE 1
Flow chart showing sample exclusions and reasons for nonreportable
samples
One trisomy 18 (T18) sample was also XXY sample and another T18 sample was also X sample. For
samples with discordant results for sequencing vs karyotype or microarray derived from testing of
amniocytes, uniplex sequencing was used for confirmation.
CNV, copy number variant; QC, quality control; T13, trisomy 13; T21, trisomy 21.
Lefkowitz et al. Clinical validation of genomewide cell-free DNA testing. Am J Obstet Gynecol 2016.
TABLE 3
Clinical performance for indicated abnormalities and fetal sex
Abnormality
Concordant
positive
Discordant
positive
Concordant
negative
Discordant
negative
Sens
(95%
T21 85 0 1081 0 100%
T18 27 0 1139 0 100%
T13 15 0 1151 0 100%
SCA 26 1 1117 0 100%
CNVsa 42 1 1122 1 97.7%
Analyte
Concordant
male
Discordant
male
Concordant
female
Discordant
female
Fetal sex 583 4 578 1
CI, confidence interval; CNVs, copy number variants; SCA, sex chromosome aneuploidy; T13, trisomy 13; T18, trisomy 18; T21, triso
a Includes 8 samples with detected whole chromosome trisomies, and 35 samples with subchromosomal CNVs.
Lefkowitz et al. Clinical validation of genomewide cell-free DNA testing. Am J Obstet Gynecol 2016.
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Among the 1166 reportable samples,
there were 85 T21 samples, 27 T18
samples, and 15 T13 samples (Figure 1).
All euploid, T21, T18, and T13 samples
(determined by invasive diagnostic
procedures) were classiﬁed correctly
by NIPT. One sample was classiﬁed
by NIPT as T21 but had a normal
(46, XX) karyotype by amniocentesis
(Supplemental Table 2). This discrep-
ancy was adjudicated through high
coverage uniplex sequencing (typically
with >180 million reads) according to
our study plan (Supplemental Figure 1,
D). The sample showed 16.3% fetal
fraction, but the gain of genetic material
from chromosome 21 was concordant
with 6.5% fetal fraction. This is sugges-
tive of conﬁned placental mosaicism, a
relatively common cause of discordant
results between amniocyte results and
CVS or placentally derived cell-free DNA
(cfDNA) analysis.8 Table 3 summarizes
the performance for T21, T18, and T13.
For T21, the sensitivity was 100% (95%
conﬁdence interval [CI], 94.6e100%)
and the speciﬁcity was 100% (95% CI,
99.6e100%). For T18, the sensitivity
was 100% (95%CI, 84.4e100%) and the
speciﬁcity was 100% (95% CI,
99.6e100%). For T13, the sensitivity
was 100% (95% CI, 74.7e100%) and
the speciﬁcity was 100% (95% CI,
99.6e100%).itivity
CI)
Specificity
(95% CI)
(94.6e100%) 100% (99.6e100%)
(84.4e100%) 100% (99.6e100%)
(74.7e100%) 100% (99.6e100%)
(84.0e100%) 99.9% (99.4e100%)
(86.2e99.9%) 99.9% (99.4e100%)
Accuracy (95% CI)
99.6% (98.9e99.8%)
my 21.
FIGURE 2
Examples of copy number variants detected by sequencing
A, Chromosome (Chr) 22 ideogram showing sequencing-based detection of 22q11.21 deletion (DiGeorge syndrome) that was confirmed by karyotype
and microarray. B, Chr 18 ideogram for sample with karyotype 46, XY, i(18)(q10). C, Chr 7 and 13 ideograms for sample with karyotype 46, XX, der(7)
t(7;13)(q36;q22).
Lefkowitz et al. Clinical validation of genomewide cell-free DNA testing. Am J Obstet Gynecol 2016.
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In the 1166 samples reportable for all
chromosomal abnormalities, there were
21 samples ﬂagged as nonreportable
speciﬁcally for SCA classiﬁcation based
on thresholds for the chromosome X Z-
score and chromosome Y Z-score as
described by Mazloom et al.20 There was
also 1 additional sample with an
apparent maternal XXX that was ﬂagged
as nonreportable for SCA because the
maternal event distorted the sex chro-
mosomal representation to a degree that
fetal events could not be classiﬁed.
Among the remaining 1144 samples
reportable for SCAs, there were 7
discordant positives that were classiﬁedas normal (46, XX) by karyotype and
as XO by sequencing at 6-plex
(Supplemental Table 2). In all discor-
dant cases, the karyotype had been ob-
tained from amniocyte samples. This
phenomenon is well described and may
be attributed to varying levels of
placental or maternal mosaicism.21
Uniplex sequencing conﬁrmed 6 of the
7 XO samples. The seventh sample had a
nonreportable result at uniplex coverage,
hence the existing amniocentesis result
was used as truth resulting in 1 false-
positive assignment. Overall, the sensi-
tivity for SCA was 100% (95% CI,
84.0e100%) with a speciﬁcity of 99.9%
(95% CI, 99.4e100%) (Table 3).AUGUST 2016 AmeriGenomewide detection of CNVs
The test was also designed to detect
CNVs 7 Mb (including whole chro-
mosome abnormalities other than T13,
T18, T21, and SCAs) as well as select
microdeletions <7 Mb.5 Among the
1166 samples reportable for sub-
chromosomal abnormalities, there were
43 samples that had positive results for a
variety of CNV aberrations: Wolf-
Hirschhorn syndrome deletions,
DiGeorge syndrome deletions, Prader-
Willi/Angelman syndrome deletions, cri
du chat syndrome deletions, and a vari-
ety of 7-Mb CNVs including both
subchromosomal CNVs and whole
chromosome trisomies. Severalcan Journal of Obstetrics& Gynecology 227.e5
FIGURE 3
Clarification of karyotype findings by sequencing of maternal plasma
Normal regions (blue). Deletions and duplications that are detected with high bootstrap confidence levels (>0.99) (red). Low bootstrap confidence events
(yellow). Chromosome (Chr) 5 and 17 ideograms are shown for sample with karyotype of 46, XX, der(5)t(5;?)(p15.3;?). Unidentified duplication on
karyotype is from Chr 17.
Lefkowitz et al. Clinical validation of genomewide cell-free DNA testing. Am J Obstet Gynecol 2016.
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conﬁrmed by microarray or karyotype
are shown in Figure 2.
Overall, the sensitivity for detection of
whole chromosome and sub-
chromosomal abnormalities other than
T13, T18, T21, and SCAs was 97.7%
(95% CI, 86.2e99.9%) and the speci-
ﬁcity was 99.9% (95% CI, 99.4e100%)
(Table 3). One case was clearly mosaic
for T22 by both standard coverage
and uniplex sequencing (Supplemental
Table 2 and Supplemental Figure 1, E),
but was classiﬁed as normal by micro-
array analysis. Because the invasive
diagnosis came frommicroarray analysis
of cells derived from CVS, our study
design considered this as the gold stan-
dard, and this outcome was considered
a discordant positive. Another case
showed no gain or loss of genetic mate-
rial with both standard and uniplex
sequencing for a sample that had a 46,
XX, der(12)t(12;19)(p13.1;q13.1) kar-
yotype (Supplemental Figure 2, B). This
outcome was considered as a discordant
negative given that the invasive proce-
dure was CVS. A set of 7 samples were
classiﬁed as full chromosomal trisomies,
and because the karyotype or microarray
results were derived from amniocytes in
these cases, uniplex sequencing was
performed for adjudication per the study
design. The trisomy ﬁnding was
conﬁrmed in each case by uniplex227.e6 American Journal of Obstetrics& Gynecolsequencing, and these ﬁndings were
considered as concordant positives
(Supplemental Figure 1).
In addition to the high accuracy
demonstrated in the results, in some
cases NIPT could also provide clariﬁca-
tion about the origin of extra genetic
material when the G-banding pattern
was not sufﬁciently clear. In 1 case, the
amniocyte karyotype ﬁnding, 46, XX,
der(5)t(5;?)(p15.3;?), indicated a dele-
tion on chromosome 5 and a duplication
of unknown origin (Figure 3). NIPT
identiﬁed an 18.6-Mb duplication rep-
resenting the entire short arm of chro-
mosome 17, indicating this fetal tissue
possessed a trisomy of chromosome 17p
that was not clariﬁed by standard kar-
yotype. Trisomy 17p is associated with
developmental delay, growth retarda-
tion, hypotonia, digital abnormalities,
congenital heart defects, and distinctive
facial features.22 Additional cases are
shown in Supplemental Figure 3.
Comment
Couples and families who are seeking
prenatal information about the genetic
health of their baby have multiple op-
tions today, ranging from noninvasive
tests that screen for select chromosomal
abnormalities to invasive procedures
including karyotype and microarray
testing that can deliver the most
comprehensive genomic assessment.ogy AUGUST 2016Current NIPT methods provide infor-
mation about a limited set of conditions
that typically include T21, T18, T13, and
SCAs. In this study we expand testing to
the entire genome. The results demon-
strate that high sensitivity and speciﬁcity
were maintained while adding genome-
wide clinically relevant content.
Most NIPT tests suffer from the
problem of multiple hypothesis testing;
whenmultiple regions of the genome are
tested independently, false-positive rates
become additive.23 This can result in
unacceptably high false-positive rates
and lead to maternal anxiety and addi-
tional unnecessary clinical testing.
Methods that target individual regions of
the genome cannot overcome these
limitations because they are part of the
design of the test.24 We have shown that
these limitations can be overcome by
using a genomewide approach, as
described here and previously.6 In this
study we demonstrate that the test can
provide excellent performance for CNVs
7Mb and select microdeletions<7Mb
across the genome.
This study does have limitations.
Although we analyze 2- to 6-fold more
samples with subchromosomal CNVs
than previous studies,6,11,24 the total
number of affected samples is still
relatively small compared to studies
validating performance for detection
of common whole chromosome
ajog.org OBSTETRICS Original Researchaneuploidies.25 It remains challenging
to statistically validate detection of rare
individual chromosomal variations. As
such we utilize samples with CNVs of
varying size and location throughout
the genome with varying frequency of
individual occurrence. This study
design with its high positivity rate al-
lows only estimation of PPV. As sensi-
tivity and speciﬁcity values have proven
stable in previous studies when applied
to the real-world samples, PPV can
be considered a function of incidence
rate. Incidence estimates of larger
karyotype-detectable genomewide sub-
chromosomal CNVs vary but are typi-
cally considered between 1 in 200 and 1
in 400.26 Modeled PPVs for these
incidence rates would therefore be be-
tween 68-83% (Supplemental Figure 4).
Due to the high sensitivity observed,
negative predictive values are expected
to be well >99.9% when incidence
rates are <1 in 200. As our study uti-
lized only 1 aliquot for analysis, our
reportable rate was 96.5%, with an
expected reportable rate of w99% with
availability of 2 aliquots.19 Of the
11 samples not reported due to the
biological effect of low fetal fraction, all
had normal karyotype result.
Another challenge commonly
observed in novel technologies with
increased performance is the compila-
tion of samples with appropriate ground
truth. In our study we face the technical
challenge of comparing sequencing vs G-
band karyotype or microarray, as well as
the biological aspect of cfDNA vs
amniocyte or CVS. We have used a
method that prioritizes CVS over
amniocentesis because of the placental
origin of cfDNA.8 Factors that can lead
to discordant results include conﬁned
placental mosaicism, maternal mosai-
cism, vanishing twins, undetected
tumors, and technical errors. Conse-
quently our method of evaluation has
the potential to overestimate perfor-
mance with regard to fetal outcome.
However, knowledge about the genetic
health of the placenta might in itself be
advantageous when guiding the preg-
nancy, for example in the case of intra-
uterine growth restriction. Prospective
studies using the method described herewith follow-up of birth outcome will
further enhance understanding of clin-
ical effectiveness.
An interesting observation in this
study was the sometimes subjective na-
ture of karyotyping. When G-banding is
used as an analytical method, the optical
resolution is occasionally not sufﬁcient
to determine the origin of additional
genetic material, making a clinical
interpretation more difﬁcult. These
ambiguities are eliminated when using
NIPT because the test requires
sequencing alignment to the genome
before DNA gains and losses are deter-
mined. However, G-banding will, for the
foreseeable future, be the superior
methodology to determine copy number
neutral structural changes.
In pregnancies that can beneﬁt from
additional information, this test pro-
vides more clinically relevant results
than previous NIPT options. However,
its role as a follow-up test to abnormal
ultrasound ﬁndings or as a general
population screen will likely be debated
for the foreseeable future. It has been
argued that the incidence of clinically
relevant subchromosomal CNVs could
be as high as 1.7% in a general popula-
tion,26 and early microarray data27
indicate that as many as 30% of sub-
chromosomal CNVs could be>7Mb. In
consequence, the incidence for these
large CNVs may be around 0.5% in the
general population, substantially higher
than the incidence of T21.
In summary, this clinical study pro-
vides validation for an approach that
extends the clinical validity of cfDNA
testing, now providing detection of T21,
T18, T13, SCAs, fetal sex, and genome-
wide detection of subchromosomal and
whole chromosomal abnormalities.
Overall, subchromosomal abnormalities
and aneuploidies other than T13, T18,
T21, and SCAs were detected with a
combined clinical sensitivity and speci-
ﬁcity of 97.7% (95% CI, 86.2e99.9%)
and 99.9% (95% CI, 99.4e100%),
respectively. This enables comprehensive
noninvasive chromosomal assessment
that was previously available only by
karyotype, and in some cases, may clarify
cryptic ﬁndings otherwise identiﬁable
only by microarray. nAUGUST 2016 AmeriAcknowledgment
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SUPPLEMENTAL TABLE 1
Breakdown of excluded and nonreported samples
Reason SampleID Fetal fraction Karyotype/microarray outcome
Exclusions
Missing invasive confirmation 53063 0.130 Normal
77320 0.079 Normal
53863 0.068 Normal
RAS0027851 0.065 Other: T16 by NIPT. SCA 46-XY
Mosaicism 54172 0.093 Normal karyotype; low level mosaic T21 by FISH
77168 0.247 Other: 46,XX,dup(1)(q21q32) - mosaic
70600 0.094 Other: 47,XX,þi(12)(p10)[13]/46,XX[2].nuc ish
(ETV6x4,AML 1/20[25/25] - tetrasomy 12p mosaicism
Vague karyotype result 72938 0.093 Other: 46,XY,var(18)(q11.2)
71894 0.114 Other: 46XX, 22qvar
54681 0.081 Other: 47, XX, þmar
72288 0.148 Other: 47, XX, þmar
54039 0.098 Other: 47, XX, þmar.ish
idic(15;15)(q13;q13)(D15Z1þþ, SNRPNþþ)
89063 0.096 Other: 47, XX, þESAC considered normal female
73189 0.089 Other: 47, XY, þESAC
Biological exclusions
Fetal fraction 55348 0.040 Normal
53720 0.036 Normal
54528 0.039 Normal
89588 0.036 Normal
89473 0.032 Normal
77411 0.019 Normal
77188 0.028 Normal
89311 0.037 Normal
53415 0.027 Normal
53801 0.036 Normal
53103 0.037 Normal
Maternal event 55197 0.065 Normal
45424 0.149 T21
Technical exclusions
Low aligned counts 77478 0.079 Normal
High variability 77065 0.087 T18
77066 0.092 T21
77068 0.083 Normal
77042 0.109 Normal
CADET 77340 0.131 Normal
55462 0.078 Normal
89583 0.082 Normal
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SUPPLEMENTAL TABLE 1
Breakdown of excluded and nonreported samples (continued)
Reason SampleID Fetal fraction Karyotype/microarray outcome
77040 0.058 Normal
GC warning 93693 0.112 Normal
77392 0.091 Normal
89526 0.105 Normal
93679 0.074 Normal
89152 0.076 Normal
53815 0.077 Normal
73161 0.161 Normal
73017 0.158 Normal
71006 0.072 Other: 46xx, add(18)(q21.3)
Laboratory director review 77075 0.104 Normal
54320 0.048 Normal
54212 0.147 Normal
77067 0.072 Normal
53061 0.043 Normal
89359 0.064 Normal
89149 0.094 Normal
53420 0.075 Normal
55112 0.092 Other: 48,XXX,þ18
Library failure 77347 0.148 Normal
54227 0.112 Normal
Nonreportable for sex chromosome aneuploidy 89529 0.106 Normal
77445 0.232 Normal
55123 0.084 Normal
89185 0.068 Normal
89607 0.076 Normal
53057 0.057 Normal
55444 0.041 Normal
54458 0.215 Normal
55220 0.068 Normal
93678 0.145 Normal
70268 0.094 Normal
53109 0.087 Normal
55454 0.047 Normal
55064 0.099 Normal
77285 0.120 Normal
55260 0.154 Normal
77157 0.042 Other: 46,XX,der(18)(qter-q11.3-qter). Additional
material added to 18p
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SUPPLEMENTAL TABLE 1
Breakdown of excluded and nonreported samples (continued)
Reason SampleID Fetal fraction Karyotype/microarray outcome
73164 0.085 Other: abnormal female karyotype with chromosome
13q deletion
45364 0.102 T18
89582 0.099 T18
77476 0.108 T21
89220 0.130 T21
CADET, Chromosomal Aberration Decision Tree; ESAC, extra structurally abnormal chromosome; FISH, fluorescent in situ hybridization; NIPT, noninvasive prenatal test; SCA, sex chromosome
aneuploidy; SNRPN, small nuclear ribonucleoprotein polypeptide N; T18, trisomy 18; T21, trisomy 21.
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SUPPLEMENTAL TABLE 2
Uniplex sequencing results for discordant samples
Category
Invasive test results Noninvasive test results
Test type Sample type Finding 6-plex 1-plex
T21 Karyotype Amniocentesis Normal T21 T21
SCA Karyotype Amniocentesis Normal X X
Karyotype Amniocentesis Normal X X
Karyotype
and microarray
Amniocentesis Normal X NR for SCA
Karyotype Amniocentesis Normal X X
Karyotype Amniocentesis Normal X X
Karyotype Amniocentesis Normal X X
Karyotype Amniocentesis Normal X X
CNVs Karyotype CVS 46, XX,
der(12)t(12;19)(p13.1;q13.1)
mat
Normal Normal
Karyotype Amniocentesis 46, XX,der(18)
(qter->q11.2::p11.3->
qter)
Normal Normal
Karyotype Amniocentesis 46, XY, add(20)(q11.2) Normal Normal
Karyotype Amniocentesis 46, XY, add(18)(p11.3) Normal Normal
Karyotype Amniocentesis Normal 9p24.3p13.1 duplication 9p24.3p13.1 duplication
Karyotype Amniocentesis Normal chr1p36.33p36.22 deletion,
chr17q25.1q25.3 duplication
chr1p36.33p36.22 deletion,
chr17q25.1q25.3 duplication
Karyotype Amniocentesis Normal T16 T16
Microarray Amniocentesis Normal T14 T14
Karyotype Amniocentesis Normal T8 T8
Karyotype Amniocentesis Normal T22 T22
Karyotype Amniocentesis Normal T16 T16
Microarray CVS Normal T22 T22
Karyotype Amniocentesis Normal T16 T16
Microarray Amniocentesis Normal T8 T8
Samples with results at 6-plex that were discordant with microarray or karyotype findings were resequenced at higher coverage for confirmation.
CNVs, copy number variants; CVS, chorionic villus sampling; SCA, sex chromosome aneuploidy; T, trisomy.
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SUPPLEMENTAL FIGURE 1
Analysis of disomy and trisomy
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SUPPLEMENTAL FIGURE 2
Analysis of sequencing and karyotypes
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SUPPLEMENTAL FIGURE 3
Analysis of karyotypes
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SUPPLEMENTAL FIGURE 4
Incidence rate
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